| Realeyes Inc | |
|
1353 Paseo Del Pueblo Sur, Suite C, Taos, NM 87571-5801 | |
| (575) 758-3215 | |
| (575) 751-9280 |
| Full Name | Realeyes Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 1353 Paseo Del Pueblo Sur, Taos, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528147865 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 474 (New Mexico) | Primary |
| Provider Name | Robert D Ratzlaff |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1164509956 PECOS PAC ID: 6305739822 Enrollment ID: I20061108000636 |
News Archive
A new study from the World Health Organization's International Agency for Research on Cancer (IARC), published in the journal Lancet Oncology, has found an association between alcohol and a substantially higher risk of several forms of cancer, including breast, colon, and oral cancers.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
TELCOR, the leading vendor truly focused on point of care testing (POCT) middleware innovations, has introduced the first interface that seamlessly updates operator demographic information and competency completion information directly from a facility's LMS/HRIS to its POCT middleware solution.
Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Realeyes Inc 1353 Paseo Del Pueblo Sur, Suite C, Taos, NM 87571-5801 Ph: (575) 758-3215 | Realeyes Inc 1353 Paseo Del Pueblo Sur, Suite C, Taos, NM 87571-5801 Ph: (575) 758-3215 |
News Archive
A new study from the World Health Organization's International Agency for Research on Cancer (IARC), published in the journal Lancet Oncology, has found an association between alcohol and a substantially higher risk of several forms of cancer, including breast, colon, and oral cancers.
ARIAD Pharmaceuticals, Inc. today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency.
TELCOR, the leading vendor truly focused on point of care testing (POCT) middleware innovations, has introduced the first interface that seamlessly updates operator demographic information and competency completion information directly from a facility's LMS/HRIS to its POCT middleware solution.
Evidence from observational studies indicates that diets rich in whole grain reduce risk of obesity and other diseases related to the metabolic syndrome e.g. type 2 diabetes and cardio-vascular disease. The mechanisms involved are only partially elucidated. Work within HEALTHGRAIN has revealed novel insights regarding some potential mechanisms.
Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
› Verified 4 days ago
Dr. Robert D Ratzlaff, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1353 Paseo Del Pueblo Sur, Suite C, Taos, NM 87571 Phone: 575-758-3215 Fax: 575-751-9280 | |
Dr. Jane Ellen Compton, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 710 F South Santa Fe Rd, Taos, NM 87571 Phone: 575-758-2205 Fax: 575-751-7102 | |
Robert Ratzlaff Od Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1128-a Paseo Del Pueblo Sur, 7653 Ndcbu, Taos, NM 87571 Phone: 505-758-3215 Fax: 505-751-9280 | |
Jane Compton Od Optometrist Medicare: Medicare Enrolled Practice Location: 710 Paseo Del Pueblo Sur Ste F, Taos, NM 87571 Phone: 575-758-2205 Fax: 575-751-7102 | |
Eye Associates Of New Mexcio Optometrist Medicare: Medicare Enrolled Practice Location: 1399 Weimer Rd, Suite 300, Taos, NM 87571 Phone: 505-758-0621 Fax: 505-758-0622 | |
Jane Compton O.d. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 710 S Santa Fe Rd Ste F, Taos, NM 87571 Phone: 575-758-2205 Fax: 575-751-7102 |